UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - A retrospective analysis

Anti-Cancer Drugs

Volumn 18, Issue 6, 2007, Pages 709-712

  Vormittag, Laurenz ^a   Kornek, Gabriela V ^a   Gruhsmann, Barbara ^a   Lenauer, Alfred ^b   Föger, Andreas ^b   Depisch, Dieter ^b   Lang, Fritz ^c   Scheithauer, Werner ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b General Hospital Wiener Neustadt   (Austria)

^c Krankenhaus Neunkirchen   (Austria)

Author keywords

Advanced colorectal cancer; Leucovorin; Mitomycin C; Salvage chemotherapy; UFT

Indexed keywords

CAPECITABINE; CETUXIMAB; FERROUS GLUCONATE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB; RALTITREXED; TIPIFARNIB; UFT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; INFECTION; INFECTION COMPLICATION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TEGAFUR; URACIL;

EID: 34548357027     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280761a9d     Document Type: Article

References (13)

1. Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005; 12:105-110.
2. Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Pippas A, Windt P, et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005; 23:255s [abstract 3536].
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
4. Hecht J, Mitchell E, Baranda J, Malik I, Richards D, Navale L, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (< 1%) levels of epidermal growth factor receptor. Proc Am Soc Clin Oncol 2006; 24:157s [abstract 3547].
5. Berlin J, Neubauer M, Swanson P, Harker WG, Burris H, Hecht JR, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > 10% epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2006; 24:158s [abstract 3548].
6. Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F, Isacoff W. Anti-VEGF antibody bevacizumab (avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 2004; 8 (Suppl 1):s50-s52.
7. Saltz LB, Lenz HJ, Hochster H, Wadler S, Hoff P, Kemeny N, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 2005; 23:248s [abstract 3508].
8. Chester JD, Dent JT, Wilson G, Ride E, Seymour MT. Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Ann Oncol 2000; 11:235-237.
9. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005; 93:510-514.
10. Scheithauer W, Kornek GV, Brugger S, Ullrich-Pur H, Valencak J, Raderer M, et al. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/ leucovorin-pretreated colorectal cancer. Cancer Invest 2002; 20:60-68.
11. Gyldenkerne N, Glimelius B, Frodin JE, Kjaer M, Pfeiffer P, Hansen F, et al. A phase II study of UFT and leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. Acta Oncol 2004; 43:276-279.
12. Lim do H, Park YS, Park BB, Ji SH, Lee J, Park KW, et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2005; 56:10-14.
13. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-1214.